Omics is a term brief for various diverse studies which includes genomics, transcriptomics, proteomics and metabolomics. The traditional transcriptomics and proteomics approaches have provided insight into disease progression by identifying discrete cellular subpopulation or micro environmental signatures characteristics of normal or pathological tissues. The spatial pattern of the genome have been identified for the treatment of various diseases because of that spatial information is being used as a diagnostic biomarker for identifying the medical condition. Special omics combines molecular analysis with spatial information on the cells localization within the tissue. Thus, this technology is providing a powerful tool to understand important mechanisms such as tissue organisation or cell regulation.
The global spatial omics market is estimated to be valued at US$ 267 million in 2022 and is expected to exhibit a CAGR of 9.4 % over the forecast period (2022-2030)
Figure 1. Global Spatial Omics Market Value (US$ Mn), By Region, 2022
Increasing cancer population worldwide is expected to drive growth of the global spatial omics market over the forecast period.
For instance, according to World Health Organisation, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. There were 1.41 million cases of prostate cancer worldwide.
|Base Year:||2021||Market Size in 2022:||US$ 267 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2022 to 2030|
|Forecast Period 2022 to 2030 CAGR:||9.4 %||2030 Value Projection:||US$ 547 Mn|
10x Genomics, Akoya Bioscience Inc., Biognosys AG, BioSpyder Technologies, Bio-Techne, Bruker, Brooks Automation Inc., Danaher Corporation, Diagenode
|Restraints & Challenges:||
Figure 2. Global Spatial Omics Market Share (%), By Product Type, 2022
The increasing product launches and approvals are expected to drive the market growth over the forecast period.
For instance, in August 2021, vizgen, the life science company dedicated to improving human health by visualizing single cell spatial genomics information has commercialized MERSCOPE platform, MERSCOPE is the only platform for MERFISH technology. MERFISH provides the highest detection efficacy available for spatially profiling gene expression across whole tissues and resolving individual transcripts with nanometre scale resolution through combinatorial labelling, sequential imaging, and error robust barcoding.
Moreover, in March 2021, Veranome Biosystems LLC, has revealed the world first complete sample to insight high plex spatial omics solution for single cell level characterization. The Pisces technology has been demonstrated to map thousands of custom gene panels in tissues at sub cellular resolution with high gene counts per cell and high sensitivity.
Global Spatial Omics Market – Impact of Coronavirus (Covid-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 193,657,725 cases and 4,154,660 deaths due to coronavirus disease (COVID-19) were reported till July 25, 2021, across the globe.
Covid-19 did have negative impact on spatial omics market in early days of covid-19 spread, with decline in the company’s revenue in the second quarter of 2020, due to widespread customer lab closures due to lockdown. However, the impact did not last longer and company’s revenue increased gradually due to increase in consumables revenue driven by growth in instrument installed base.
For instance, the revenue of 10x Genomics of the fourth quarter of 2020 was 112.2 million with 49% increase in the revenue which was 75.3 in the third quarter.
Global Spatial Omics Market Restraint
Spatial omics is relatively new area of research, the global development of spatial transcriptomics research has been concentrated in the U.S and other developed countries. Moreover limited research expertise is available in this field and lack of skilled professionals.
Major players operating in the global spatial omics market include 10x Genomics, Akoya Bioscience Inc., Biognosys AG, BioSpyder Technologies, Bio-Techne, Bruker, Brooks Automation Inc., Danaher Corporation, Diagenode Diagnostics, Fluidigm Corporation, IonPath Inc., Millennium Science Pty Ltd, NanoString Technologies, PerkinElmer, Rebus Biosystems, Ultivue Inc., Vizgen Corp, Dovetail Genomics, S2 Genomics, Inc., Seven Bridges Genomics.
Spatial omics technologies have emerged during the last few years and have changed the way we understand multicellular biological systems, which includes genomics, transcriptomics, proteomics, and metabolomics.
Conventional proteomics and transcriptomics have provided granular insights into disease proliferation via identification of discrete cell population along with other pathological issues. Moreover, spatial omics methods provide high resolution mapping of expression profiles of cell tissues similar to that provided by mass spectrometry. Ability to retain spatial content of various cells in samples along with their cellular geometry and surrounding extracellular matrix (ECM) is likely to offer spatial omics with an opportunity to explore unexplored signal modalities.
Surge in acceptance of spatial genomics by start-ups and small firms along with its massive use in biomarker identification will drive the market, in addition to this, rise in application of spatial genomics in drug development and medicine discovery will create lucrative avenues for spatial omics industry.
The increasing population of cancers, rising research and development activities, and increasing adoption of inorganic growth strategies such as mergers, acquisitions, partnerships, and collaborations by key players operating in the market are the major factors that are expected to drive growth of the global spatial omics market over the forecast period.
According to American Cancer Society, in the U.S in 2022, about 99,780 new melanomas will be diagnosed (about 57,180 in men and 42,600 in women) and about 7,650 people are expected to die of melanoma (about 5,080 men and 2,570 women).
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.